Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Stevens-Johnson Syndrome

  • Author: C Stephen Foster, MD, FACS, FACR, FAAO, FARVO; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Nov 09, 2015
 

Practice Essentials

Stevens-Johnson syndrome is an immune-complex–mediated hypersensitivity complex that typically involves the skin and the mucous membranes. Although several classification schemes have been reported, the simplest classification breaks the disease down as follows[1] :

  • Stevens-Johnson syndrome: A minor form of toxic epidermal necrolysis, with less than 10% body surface area (BSA) detachment
  • Overlapping Stevens-Johnson syndrome/toxic epidermal necrolysis: Detachment of 10-30% of the BSA
  • Toxic epidermal necrolysis: Detachment of more than 30% of the BSA

Signs and symptoms

Typical prodromal symptoms of Stevens-Johnson syndrome are as follows:

  • Cough productive of a thick, purulent sputum
  • Headache
  • Malaise
  • Arthralgia

Patients may complain of a burning rash that begins symmetrically on the face and the upper part of the torso. The cutaneous lesions are characterized as follows:

  • The rash can begin as macules that develop into papules, vesicles, bullae, urticarial plaques, or confluent erythema
  • The typical lesion has the appearance of a target; this is considered pathognomonic
  • In contrast to the typical lesions of erythema multiforme, these lesions have only 2 zones of color
  • The lesion’s core may be vesicular, purpuric, or necrotic; that zone is surrounded by macular erythema
  • Lesions may become bullous and later rupture, leaving denuded skin; the skin becomes susceptible to secondary infection
  • Urticarial lesions typically are not pruritic
  • Infection may be responsible for the scarring associated with morbidity
  • Although lesions may occur anywhere, the palms, soles, dorsum of the hands, and extensor surfaces are most commonly affected
  • The rash may be confined to any one area of the body, most often the trunk

Signs of mucosal involvement can include the following:

  • Erythema
  • Edema
  • Sloughing
  • Blistering
  • Ulceration
  • Necrosis

The following ocular signs may be noted on slit-lamp examination:

  • Eyelids: Trichiasis, distichiasis, meibomian gland dysfunction, blepharitis
  • Conjunctiva: Papillae, follicles, keratinization, subepithelial fibrosis, conjunctival shrinkage, foreshortening of fornices, symblepharon, ankyloblepharon
  • Cornea: Superficial punctate keratitis, epithelial defect, stromal ulcer, neovascularization, keratinization, limbitis, conjunctivalization, stromal opacity, perforation (see the image below)
    A patient with severe eye involvement associated w A patient with severe eye involvement associated with Stevens-Johnson syndrome. Note corneal neovascularization and conjunctivalization of the ocular surface.

See Clinical Presentation for more detail.

Diagnosis

Minimal dermal inflammatory cell infiltrate and full-thickness necrosis of the epidermis are typical histopathologic findings in patients with Stevens-Johnson syndrome. Histopathologic examination of the skin can also reveal the following:

  • Changes in the epidermal-dermal junction ranging from vacuolar alteration to subepidermal blisters
  • Dermal infiltrate: Superficial and mostly perivascular
  • Apoptosis of keratinocytes
  • CD4+ T lymphocytes predominating in the dermis; CD8+ T lymphocytes predominating in the epidermis; the dermoepidermal junction and epidermis is infiltrated mostly by CD8+ T lymphocytes

Ocular examination can demonstrate the following:

  • Conjunctival biopsies from patients with active ocular disease show subepithelial plasma cells and lymphocyte infiltration; lymphocytes also are present around vessel walls; the predominant infiltrating lymphocyte is the helper T cell
  • Immunohistology of the conjunctiva reveals numerous HLA-DR–positive cells in the substantia propria, vessel walls, and epithelium

See Workup for more detail.

Management

Most patients with Stevens-Johnson syndrome are treated symptomatically. In principle, the symptomatic treatment of patients with this disorder does not differ from the therapy applied to patients with extensive burns.

Patients should be treated with special attention to airway and hemodynamic stability, fluid status, wound/burn care, and pain control. Therapy for Stevens-Johnson syndrome proceeds as follows:

  • Withdrawal of any agent suspected of causing the condition is critically important
  • Oral lesions are managed with mouthwashes; topical anesthetics are useful in reducing pain and allowing the patient to take in fluids
  • Areas of denuded skin must be covered with compresses of saline or Burow solution
  • Tetanus prophylaxis must be addressed

Extensive debridement of nonviable epidermis followed by immediate cover with biologic dressings is among the recommended treatments.

Ocular therapy

The treatment of acute ocular manifestations usually begins with aggressive lubrication of the ocular surface. As inflammation and cicatricial changes ensue, most ophthalmologists use topical steroids, antibiotics, and symblepharon lysis.

In the case of mild chronic superficial keratopathy, long-term lubrication may be sufficient. In cases of severe ocular involvement, treatment includes the following:

  • Removal of keratinized plaques from the posterior lid margins
  • Mucous membrane grafting and/or amniotic membrane grafting
  • Limbal stem cell transplantation and amniotic membrane grafting
  • Superficial keratectomy removing conjunctivalized or keratinized ocular surface

See Treatment and Medication for more detail.

Next

Background

Stevens-Johnson syndrome (SJS) is an immune-complex–mediated hypersensitivity complex that typically involves the skin and the mucous membranes. While minor presentations may occur, significant involvement of oral, nasal, eye, vaginal, urethral, gastrointestinal, and lower respiratory tract mucous membranes may develop in the course of the illness. GI and respiratory involvement may progress to necrosis. Stevens-Johnson syndrome is a serious systemic disorder with the potential for severe morbidity and even death.

The syndrome was first described in 1922, when the American pediatricians Albert Mason Stevens and Frank Chambliss Johnson reported the cases of 2 boys aged 7 and 8 years with "an extraordinary, generalized eruption with continued fever, inflamed buccal mucosa, and severe purulent conjunctivitis." Both cases had been misdiagnosed by primary care physicians as hemorrhagic measles.

Erythema multiforme (EM), originally described by von Hebra in 1866, was part of the differential diagnosis in both cases but was excluded because of the "character of skin lesions, the lack of subjective symptoms, the prolonged high fever, and the terminal heavy crusting." Despite the presence of leukopenia in both cases, Stevens and Johnson in their initial report suspected an infectious disease of unknown etiology as the cause.

In 1950, Thomas divided EM into 2 categories: erythema multiforme minor (von Hebra) and erythema multiforme major (EMM). Since 1983, erythema multiforme major and Stevens-Johnson syndrome had been considered synonymous.

In the 1990s, however, Bastuji and Roujeau each proposed that erythema multiforme major and Stevens-Johnson syndrome are 2 distinct disorders.[2] They suggested that the denomination of erythema multiforme should be restricted to patients with typical targets or raised edematous papules, with or without mucosal involvement. This clinical picture is in accordance with the original description by von Hebra.

Bastuji and Roujeau further proposed that the denomination of Stevens-Johnson syndrome should be used for a syndrome characterized by mucous membrane erosions and widespread small blisters that arise on erythematous or purpuric maculae that are different from classic targets.

According to this clinical classification, erythema multiforme major and Stevens-Johnson syndrome could be 2 distinct disorders with similar mucosal erosions, but different patterns of cutaneous lesions. This hypothesis is supported further by a strong correlation between clinical classification and the probable cause.

Conversely, several investigators propose that Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) represent the same disease at different levels of severity. A unifying classification of "acute disseminated epidermal necrosis" or "exanthematic necrolysis" has been suggested.

Although several classification schemes have been reported, the simplest breaks the disease down as follows[1] :

  • Stevens-Johnson syndrome - A "minor form of TEN," with less than 10% body surface area (BSA) detachment
  • Overlapping Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) - Detachment of 10-30% BSA
  • Toxic epidermal necrolysis - Detachment of more than 30% BSA

An argument against this unifying concept was that HSV infection had been described as a frequent cause of Stevens-Johnson syndrome/erythema multiforme major but not of toxic epidermal necrolysis. However, reports showed that HSV infection has not been related to Stevens-Johnson syndrome, and suggested that clinical manifestations and pathology results support the linking of Stevens-Johnson syndrome and toxic epidermal necrolysis, and their differentiation from erythema multiforme.

Various etiologic factors (eg, infection, drugs, malignancies) have been implicated as causes of Stevens-Johnson syndrome. However, as many as half of cases are idiopathic. There is strong evidence for a genetic predisposition to Stevens-Johnson syndrome provoked by certain drugs. (See Etiology.)

There are no specific laboratory studies (other than biopsy) that can definitively establish the diagnosis of Stevens-Johnson syndrome (see Clinical and Workup). No specific treatment of Stevens-Johnson syndrome is noted; most patients are treated symptomatically. In principle, the symptomatic treatment of patients with Stevens-Johnson syndrome does not differ from the treatment of patients with extensive burns. Withdrawal of the suspected offending agent is critically important. Immunomodulatory treatment is controversial. (See Treatment.)

For patient education information, see the Skin, Hair, and Nails Center, as well as Life-Threatening Skin Rashes.

Previous
Next

Pathophysiology

An idiosyncratic, delayed hypersensitivity reaction has been implicated in the pathophysiology of Stevens-Johnson syndrome. Certain population groups appear more susceptible to develop Stevens-Johnson syndrome than the general population. Slow acetylators, patients who are immunocompromised (especially those infected with HIV[3, 4] ), and patients with brain tumors undergoing radiotherapy with concomitant antiepileptics are among those at most risk.

Slow acetylators are people whose liver cannot completely detoxify reactive drug metabolites. For example, patients with sulfonamide-induced toxic epidermal necrolysis have been shown to have a slow acetylator genotype that results in increased production of sulfonamide hydroxylamine via the P-450 pathway. These drug metabolites may have direct toxic effects or may act as haptens that interact with host tissues, rendering them antigenic.[5, 6]

Antigen presentation and production of tumor necrosis factor (TNF)–alpha by the local tissue dendrocytes results in the recruitment and augmentation of T-lymphocyte proliferation and enhances the cytotoxicity of the other immune effector cells.[7] A "killer effector molecule" has been identified that may play a role in the activation of cytotoxic lymphocytes.[8] The activated CD8+ lymphocytes, in turn, can induce epidermal cell apoptosis via several mechanisms, which include the release of granzyme B and perforin.

In 1997, Inachi et al demonstrated perforin-mediated apoptosis in patients with Stevens-Johnson syndrome.[9] Perforin, a pore-making monomeric granule released from natural killer cells and cytotoxic T lymphocytes, kills target cells by forming polymers and tubular structures not unlike the membrane attack complex of the complement system.

Apoptosis of keratinocytes can also take place as a result of ligation of their surface death receptors with the appropriate molecules. Those can trigger the activation of the caspase system, leading to DNA disorganization and cell death.[10]

Apoptosis of keratinocytes can be mediated via direct interaction between the cell-death receptor Fas and its ligand. Both can be present on the surfaces of the keratinocytes. Alternatively, activated T-cells can release soluble Fas ligand and interferon-gamma, which induces Fas expression by keratinocytes.[1] Researchers have found increased levels of soluble Fas ligand in the sera of patients with SJS/TEN before skin detachment or onset of mucosal lesions.[11]

The death of keratinocytes causes separation of the epidermis from the dermis. Once apoptosis ensues, the dying cells provoke recruitment of more chemokines. This can perpetuate the inflammatory process, which leads to extensive epidermal necrolysis.[12]

Higher doses and rapid introduction of allopurinol[13] and lamotrigine[14] may also increase the risk of developing SJS/TEN. Risk is lessened by starting these at the low doses and titrating gradually.[15]

There is evidence that systemic lupus is a risk factor as well.[16]

Previous
Next

Etiology

Various etiologic factors have been implicated as causes of Stevens-Johnson syndrome. Drugs most commonly are blamed. The 4 etiologic categories are as follows:

  • Infectious
  • Drug-induced
  • Malignancy-related
  • Idiopathic

Stevens-Johnson syndrome is idiopathic in 25-50% of cases. Drugs and malignancies are most often implicated as the etiology in adults and elderly persons. Pediatric cases are related more often to infections.

Infectious causes

Viral diseases that have been reported to cause Stevens-Johnson syndrome include the following:

  • Herpes simplex virus (possibly; remains a debated issue)
  • AIDS
  • Coxsackie viral infections
  • Influenza
  • Hepatitis
  • Mumps

In children, Epstein-Barr virus and enteroviruses have been identified. More than half of the patients with Stevens-Johnson syndrome report a recent upper respiratory tract infection.

Bacterial etiologies include the following:

  • Group A beta-hemolytic streptococci
  • Diphtheria
  • Brucellosis
  • Lymphogranuloma venereum
  • Mycobacteria
  • Mycoplasma pneumoniae [17, 18]
  • Rickettsial infections
  • Tularemia
  • Typhoid

Possible fungal causes include coccidioidomycosis, dermatophytosis, and histoplasmosis. Malaria and trichomoniasis have been reported as protozoal causes.

Drug-induced

Antibiotics are the most common cause of Stevens-Johnson syndrome, followed by analgesics, cough and cold medication, NSAIDs, psychoepileptics, and antigout drugs. Of antibiotics, penicillins and sulfa drugs are prominent; ciprofloxacin has also been reported[19]

The following anticonvulsants have been implicated:

  • Phenytoin
  • Carbamazepine
  • oxcarbazepine (Trileptal)
  • Valproic acid
  • Lamotrigine
  • Barbiturates

Mockenhapupt et al stressed that most anticonvulsant-induced SJS occurs in the first 60 days of use.[20]

Antiretroviral drugs implicated in Stevens-Johnson syndrome include nevirapine and possibly other non-nucleoside reverse transcriptase inhibitors.[21] Indinavir has been mentioned.

Stevens-Johnson syndrome has also been reported in patients taking the following drugs:

  • Modafinil (Provigil)
  • Allopurinol [22]
  • Mirtazapine [23]
  • TNF-alpha antagonists (eg, infliximab, etanercept, adalimumab) [24]
  • Cocaine
  • Sertraline
  • Pantoprazole
  • Tramadol

Genetic factors

There is strong evidence for a genetic predisposition to severe cutaneous adverse drug reactions such as Stevens-Johnson syndrome. Carriage of the following human leukocyte antigens has been associated with increased risk:

  • HLA-B*1502
  • HLA-B*5801
  • HLA-B*44
  • HLA-A29
  • HLA-B12
  • HLA-DR7
  • HLA-A2
  • HLA-B*5801
  • HLA-A*0206
  • HLA-DQB1*0601

Certain of these HLA alleles are associated with an increased probability of developing Stevens-Johnson syndrome upon exposure to specific drugs. The US Food and Drug Administration (FDA) and Health Canada advise screening for HLA-B*1502 in patients of southeastern Asian ethnicity before starting treatment with carbamazepine. (The risk is much lower in other ethnic populations, making screening impractical in them). HLA-B*5801 confers a risk of allopurinol-related reactions.[25] Pretreatment screening is not readily available.[26]

Whites with HLA-B*44 appear to be more susceptible to develop Stevens-Johnson syndrome. HLA-A29, HLA-B12, and HLA-DR7 are frequently associated with sulfonamide-induced Stevens-Johnson syndrome, while HLA-A2 and HLA-B12 are often encountered in Stevens-Johnson syndrome induced by nonsteroidal anti-inflammatory drugs (NSAIDs).

HLA-A*0206 and HLA-DQB1*0601 allele have been shown to be was strongly associated with Stevens-Johnson syndrome with ocular disease.[27, 28]

Nevertheless, whether the presence of those genes constitutes a predisposition to Stevens-Johnson syndrome or whether those genes are in linkage disequilibrium with more relevant adjacent genes is unknown.[29]

Previous
Next

Epidemiology

Strom et al reviewed Medicaid billing data from 1980-1984 in Michigan, Minnesota, and Florida to determine the incidence of Stevens-Johnson syndrome; the incidence rates were 7.1, 2.6, and 6.8 cases per million population per year, respectively.[30]

Cases tend to have a propensity for the early spring and winter.

For overlapping SJS and TEN, oxicam NSAIDs (piroxicam, meloxicam, tenoxicam) and sulfonamides are most commonly implicated in the United States and other western nations.[26]

SJS occurs with a worldwide distribution similar in etiology and occurrence to that in the United States. However, a study from Germany reported only 1.1 cases per 1 million person-years.

In contrast to the drugs most often implicated in western nations, allopurinol is the most common offending agent in Southeast Asian nations, including Malaysia, Singapore, Taiwan, and Hong Kong.[26]

Race-, sex-, and age-related demographics

Stevens-Johnson syndrome has been described worldwide in all races, although it may be more common in whites. Interestingly, disease is not limited to humans; cases have been reported in dogs, cats, and monkeys.

The proportion of females has been estimated to be 33-62%. The largest series reports 39.9% of females in a group of 315 patients with Stevens-Johnson syndrome.

In a large cohort, the mean age of patients with Stevens-Johnson syndrome was 25 years. In a smaller series, the mean age of patients with Stevens-Johnson syndrome was reported as 47 years. However, cases have been reported in children as young as 3 months.

Previous
Next

Prognosis

Individual lesions typically should heal within 1-2 weeks, unless secondary infection occurs. Most patients recover without sequelae.

Mortality is determined primarily by the extent of skin sloughing. When body surface area (BSA) sloughing is less than 10%, the mortality rate is approximately 1-5%. However, when more than 30% BSA sloughing is present, the mortality rate is between 25% and 35%, and may be as high as 50%.[31, 26] Bacteremia and sepsis appear to play a major role in increased mortality.[32]

The SCORTEN score (a severity-of-illness score for toxic epidermal necrolysis) calculates the risk for death in both SJS and TEN on the basis of the following variables:

  • Age >40 years
  • Malignancy
  • Heart rate >120
  • Initial percentage of epidermal detachment >10%
  • Blood urea nitrogen (BUN) level >10 mmol/L
  • Serum glucose level >14 mmol/L
  • Bicarbonate level < 20 mmol/L

Each variable is assigned a value of 1 point. Mortality rates are as follows:

  • 0-1 points, ≥3.2%
  • 2 points, ≥12.1%
  • 3 points, ≥35.3%
  • 4 points, ≥58.3%
  • 5 or more points, ≥90%

Other negative prognostic factors include persistent neutropenia (defined as neutropenia lasting more than 5 days), hypoalbuminemia (usually < 2 g/dL), and persistent azotemia.

In a survival analysis of a cohort of patients with either Stevens-Johnson syndrome or toxic epidermal necrolysis, Sekula et al found that the severity of the cutaneous reaction causing either of these disorders was a risk factor for mortality, but only during the first 90 days following reaction onset.[33] The investigators also found that serious comorbidities and age were risk factors for mortality after 90 days, but not beyond 1 year, past reaction onset. Mortality among patients was 23% at 6 weeks and 34% at 1 year.

Although some patients rapidly progress to lose very large areas of the epidermis in a matter of days, the process suddenly ceases in others and reepithelialization begins a few days later. Predicting the course of disease in a given patient at the initial presentation is not possible. Reepithelialization is usually complete within 3 weeks, but pressure and mucosal areas may remain eroded and crusted for 2 weeks or longer.

Survivors of Stevens-Johnson syndrome may experience numerous long-term sequelae; the most disabling are those of the eye. Cicatrization of conjunctival erosions may lead to the following:

  • Inverted eyelashes
  • Photophobia
  • A burning sensation in the eyes
  • Watery eyes
  • A siccalike syndrome
  • Corneal and conjunctival neovascularization

As many as 40% of survivors of toxic epidermal necrolysis have residual potentially disabling lesions that may cause blindness.

Previous
 
 
Contributor Information and Disclosures
Author

C Stephen Foster, MD, FACS, FACR, FAAO, FARVO Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution

C Stephen Foster, MD, FACS, FACR, FAAO, FARVO is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association of Immunologists, American College of Rheumatology, American College of Surgeons, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, American Uveitis Society, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, Royal Society of Medicine, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Steven J Parrillo, DO, FACOEP, FACEP Clinical Adjunct Professor, Medical Director and Faculty, Disaster Medicine and Management Masters Program, Philadelphia University College of Health Sciences; Associate Professor, Clinical and Educational Scholarship Track, Jefferson Medical College of Thomas Jefferson University; Director, Division of EMS and Disaster Medicine, Albert Einstein Healthcare Network

Steven J Parrillo, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, American Osteopathic Association, World Association for Disaster and Emergency Medicine

Disclosure: Nothing to disclose.

Erik Letko, MD Corneal Consultants of Colorado

Disclosure: Nothing to disclose.

Rola Ba-Abbad, MBBS, FRCS(Glasg) Doctoral Candidate and Medical Retina Fellow, Department of Visual Neuroscience and Moorfields Eye Hospital, UCL Institute of Ophthalmology, University of London, UK

Rola Ba-Abbad, MBBS, FRCS(Glasg) is a member of the following medical societies: Association for Research in Vision and Ophthalmology, Royal College of Physicians and Surgeons of Glasgow

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Acknowledgements

Daniel J Dire, MD, FACEP, FAAP, FAAEM Clinical Professor, Department of Emergency Medicine, University of Texas Medical School at Houston; Clinical Professor, Department of Pediatrics, School of Medicine, University of Texas Health Sciences Center San Antonio

Daniel J Dire, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, and Association of Military Surgeons of the US

Disclosure: Talecris Biotherapeutics Honoraria Speaking and teaching

Mark T Duffy, MD, PhD Consulting Staff, Division of Oculoplastic, Orbito-facial, Lacrimal and Reconstructive Surgery, Green Bay Eye Clinic, BayCare Clinic; Medical Director, Advanced Cosmetic Solutions, A BayCare Clinic

Mark T Duffy, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Sigma Xi, and Society for Neuroscience

Disclosure: Allergan - Botox Cosmetic Honoraria Speaking and teaching

Kilbourn Gordon III, MD, FACEP Urgent Care Physician

Kilbourn Gordon III, MD, FACEP is a member of the following medical societies: American Academy of Ophthalmology and Wilderness Medical Society

Disclosure: Nothing to disclose.

John D Halamka, MD, MS Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Catherine V Parrillo, DO, FACOP, FAAP, Retired Clinical Assistant Professor, Department of Pediatrics, Philadelphia College of Osteopathic Medicine

Catherine V Parrillo, DO, FACOP, FAAP, is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Matthew M Rice, MD, JD, FACEP Senior Vice President, Chief Medical Officer, Northwest Emergency Physicians of TeamHealth; Assistant Clinical Professor of Medicine, University of Washington School of Medicine

Matthew M Rice, MD, JD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, National Association of EMS Physicians, Society for Academic Emergency Medicine, and Washington State Medical Association

Disclosure: Team Health Salary Employment

Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006 Mar. 55(1):9-16. [Medline].

  2. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997 Nov. 24(11):726-9. [Medline].

  3. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003. 83(1):1-9. [Medline].

  4. Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol. 2003 Feb. 111(2 Suppl):S548-59. [Medline].

  5. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003 Aug. 139(8):1051-9. [Medline].

  6. Assier-Bonnet H, Aractingi S, Cadranel J, Wechsler J, Mayaud C, Saiag P. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol. 1996 Nov. 135(5):864-6. [Medline].

  7. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007 Aug. 91(8):1048-53. [Medline]. [Full Text].

  8. Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2010 Mar. 125(3):703-10, 710.e1-710.e8. [Medline].

  9. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol. 1997 Jul. 133(7):845-9. [Medline].

  10. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology. 1988 Apr. 95(4):453-62. [Medline].

  11. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008 Nov. 122(5):992-1000. [Medline].

  12. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006 Apr. 6(4):543-9. [Medline].

  13. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008 Jan. 58(1):25-32. [Medline].

  14. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia. 1998. 39 Suppl 7:S22-6. [Medline].

  15. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005 Apr 12. 64(7):1134-8. [Medline].

  16. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006 Feb. 5(2):160-4. [Medline].

  17. Hillebrand-Haverkort ME, Budding AE, bij de Vaate LA, van Agtmael MA. Mycoplasma pneumoniae infection with incomplete Stevens-Johnson syndrome. Lancet Infect Dis. 2008 Oct. 8(10):586-7. [Medline].

  18. Sendi P, Graber P, Lepère F, Schiller P, Zimmerli W. Mycoplasma pneumoniae infection complicated by severe mucocutaneous lesions. Lancet Infect Dis. 2008 Apr. 8(4):268. [Medline].

  19. Hällgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol. 2003 Nov. 49(5 Suppl):S267-9. [Medline].

  20. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005 Apr 12. 64(7):1134-8. [Medline].

  21. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol. 2001 Feb. 44(2 Suppl):354-7. [Medline].

  22. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008 Jan. 58(1):25-32. [Medline].

  23. Belkahia A, Hillaire-Buys D, Dereure O, Guillot B, Raison-Peyron N. Stevens-Johnson syndrome due to mirtazapine - first case. Allergy. 2009 Oct. 64(10):1554. [Medline].

  24. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol. 2009 Sep 21. 15(35):4449-52. [Medline]. [Full Text].

  25. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007. 87(2):144-8. [Medline].

  26. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ. 2010 Mar 23. 182(5):476-80. [Medline]. [Full Text].

  27. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin. 2005 Fall. 45(4):25-48. [Medline].

  28. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006 Sep. 97(3):272-80; quiz 281-3, 320. [Medline].

  29. Meth MJ, Sperber KE. Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. Mt Sinai J Med. 2006 Sep. 73(5):769-76. [Medline].

  30. Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991 Jun. 127(6):831-8. [Medline].

  31. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 Aug. 115(2):149-53. [Medline].

  32. de Prost N, Ingen-Housz-Oro S, Duong T, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010 Jan. 89(1):28-36. [Medline].

  33. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al. Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Invest Dermatol. 2013 Feb 7. [Medline].

  34. Vera LS, Gueudry J, Delcampe A, et al. In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Cornea. 2009 May. 28(4):401-7. [Medline].

  35. Shammas MC, Lai EC, Sarkar JS, Yang J, Starr CE, Sippel KC. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010 Feb. 149(2):203-213.e2. [Medline].

  36. Tseng SC. Acute management of Stevens-Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae. Am J Ophthalmol. 2009 Jun. 147(6):949-51. [Medline].

  37. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Piérard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000 Oct. 22(5):413-7. [Medline].

  38. Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009 Apr. 116(4):685-90. [Medline].

  39. Sotozono C, Ueta M, Kinoshita S. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Am J Ophthalmol. 2010 Feb. 149(2):354; author reply 355. [Medline].

  40. Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009 Jun. 147(6):1004-11, 1011.e1. [Medline].

  41. Koh MJ, Tay YK. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010 Jan. 62(1):54-60. [Medline].

  42. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest. 1990 Aug. 98(2):331-6. [Medline].

  43. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995 Nov. 102(11):1669-76. [Medline].

  44. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol. 2004 Feb. 50(2):286-8. [Medline].

  45. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008 Jan. 58(1):33-40. [Medline].

  46. Pehr K. The EuroSCAR study: cannot agree with the conclusions. J Am Acad Dermatol. 2008 Nov. 59(5):898-9; author reply 899-900. [Medline].

  47. Power WJ, Saidman SL, Zhang DS, et al. HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 1996 Sep. 103(9):1406-9. [Medline].

  48. FDA Drug Safety Communication. FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. Available at http://www.fda.gov/Drugs/DrugSafety/ucm363041.htm. Accessed: August 4, 2013.

  49. Lowes R. Acetaminophen poses risk for rare but fatal skin reactions. Medscape Medical News. August 1, 2013. [Full Text].

  50. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015 Oct 19. [Medline].

 
Previous
Next
 
A patient with severe eye involvement associated with Stevens-Johnson syndrome. Note corneal neovascularization and conjunctivalization of the ocular surface.
Epithelial defect of the cornea with neovascularization and surface conjunctivalization.
Note extensive sloughing of epidermis from Stevens-Johnson syndrome. Courtesy of David F. Butler, MD.
Sheetlike desquamation on the foot in a patient with toxic epidermal necrolysis. Courtesy of Robert Schwartz, MD.
Hemorrhagic crusting of the mucous membranes in toxic epidermal necrolysis. Similar lesions are seen in Stevens-Johnson syndrome. Courtesy of Robert Schwartz, MD.
Note early cutaneous slough with areas of violaceous erythema.
Extensive sloughing on the face.
Note the presence of both 2-zoned atypical targetoid lesions and bullae.
Extensive blistering and sloughing on the back.
Extensive sloughing on the back.
Note extensive sloughing.
Low-power view showing full-thickness epidermal necrosis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.